Skip to content

The Neural Basis of Oxytocin's Effects on Empathy

The Neural Basis of Oxytocin's Effects on Empathy

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03084029
Enrollment
72
Registered
2017-03-20
Start date
2016-01-31
Completion date
2017-09-30
Last updated
2018-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

oxytocin, fMRI, empathy

Brief summary

The main focus of this study is to examine oxytocin effects on behavioral and neural indices of empathy processing.

Detailed description

The neuropeptide oxytocin (OXT) has been demonstrated to modulate empathy in previous behavioural studies. The present study aims at replicating previous findings on OXT on empathy as well as to determine the neural basis of these effects. In a between-subject, randomized double-blind design, subjects will be either administered intranasal OXT or placebo nasal spray (40 IU). 45 minutes after administration subjects will undergo (fMRI) tasks of empathic processing. During the tasks subjects will be shown empathy inducing stimuli, and the behavioral and neural response in terms of cognitive, emotional and indirect emotional empathy will be assessed. Before the administration of treatment, validated questionnaires assessing potential confounding variables, such as depression (Becks Depression Inventory (BDI)) or mood (Positive And Negative Affect Scale (PANAS)) will be administered to the subjects.

Interventions

DRUGOxytocin

40 international units

DRUGPlacebo

40 international units

Sponsors

University of Electronic Science and Technology of China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects without past or current psychiatric or neurological disorders * no smoking at least 12 hours before experiment * no alcohol, coffee or other stimulant drinking at least 12 hours before experiment

Exclusion criteria

* mental implants * pregnancy * uterine cavity operations * use of medication * acute physical disorder

Design outcomes

Primary

MeasureTime frameDescription
Neural processing of empathy as assessed using fMRI45-115 minutes after single dose administrationMain effects of treatment and interaction between treatment effects and sex will be assessed on brain activity and connectivity in core regions of the empathy networks during processing of empathy inducing pictures

Secondary

MeasureTime frameDescription
Behavioral ratings of subjective experienced empathy processing45-115 minutes after single dose administrationMain effects of treatment and interaction between treatment effects and sex will be assessed on subjective feelings of empathy (ratings on a Likert scale in response to empathy inducing pictures).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026